GPC Biotech Reports that Marketing Authorization Application for satraplatin is to be Withdrawn
GPC Biotech Reports that Marketing Authorization Application for Satraplatin is to be Withdrawn GPC Biotech AG / Misc. matters / GPC Biotech Reports that Marketing Authorization Application for Satraplatin is to be Withdrawn
LONDON, Sept. 23, 2010-The European Medicines Agency today recommended the suspension of the marketing authorisations for the rosiglitazone-containing anti-diabetes medicines Avandia, Avandamet and Avaglim.